Recommended Enclomiphene Dose for Secondary Hypogonadism
For adult men with secondary hypogonadal testosterone deficiency, enclomiphene citrate 12.5–25 mg daily is the evidence-based dose that consistently restores testosterone to the mid-normal range (450–600 ng/dL) while preserving fertility.
Dosing Regimen
Start with enclomiphene 12.5 mg orally once daily, as this dose effectively raises serum testosterone into the normal range in men with secondary hypogonadism 1.
Titrate to 25 mg daily if needed after 6–12 weeks if testosterone remains below target (< 450 ng/dL) or symptoms persist 1, 2.
The 25 mg daily dose achieved mean testosterone levels of 604 ± 160 ng/dL after 6 weeks of treatment in clinical trials, comparable to transdermal testosterone gel 1.
Lower doses (6.25 mg daily) also raise testosterone but may be insufficient for some patients to reach mid-normal levels 1.
Mechanism and Hormonal Effects
Enclomiphene is a selective estrogen receptor antagonist that blocks negative feedback at the hypothalamus and pituitary, thereby increasing endogenous LH and FSH secretion 1, 3, 4.
This stimulates the testes to produce testosterone naturally, unlike exogenous testosterone which suppresses the hypothalamic-pituitary-gonadal axis 3, 4.
After 3–6 months of treatment, enclomiphene consistently elevates LH and FSH above baseline while maintaining or increasing sperm counts 1, 3, 2.
Fertility Preservation Advantage
Enclomiphene is the preferred option for men with secondary hypogonadism who desire fertility, because it maintains or increases sperm production while normalizing testosterone 3, 2.
In clinical trials, enclomiphene raised sperm concentrations to 75–334 × 10⁶/mL in all treated men, whereas testosterone gel suppressed sperm counts below 20 × 10⁶/mL 3, 2.
Testosterone replacement therapy is absolutely contraindicated in men seeking fertility, as it causes prolonged azoospermia 5, 6.
Monitoring Protocol
Measure morning total testosterone (8–10 AM) at 6–12 weeks after starting therapy to assess response and guide dose adjustment 5, 1.
Target mid-normal testosterone levels of 450–600 ng/dL 5, 7.
Check LH and FSH at follow-up; both should be elevated or in the upper-normal range, confirming restoration of the hypothalamic-pituitary axis 1, 3.
Obtain semen analysis at 3 and 6 months if fertility is a concern, as enclomiphene maintains or improves sperm counts 3, 2.
Continue monitoring testosterone every 6–12 months once stable 5.
Expected Clinical Outcomes
Testosterone levels rise within 2 weeks and plateau by 6 weeks of daily dosing 1, 2.
Improvements in sexual function and libido are modest but statistically significant (standardized mean difference ≈ 0.35), similar to testosterone replacement 5.
Effects on testosterone and LH persist for at least one week after stopping treatment 1.
Enclomiphene does not significantly affect lipid profiles, thyroid function, or bone markers 1.
When Enclomiphene Is Appropriate
Secondary hypogonadism confirmed by two morning testosterone measurements < 300 ng/dL with low or low-normal LH/FSH 5, 6, 1.
Men who wish to preserve fertility while treating testosterone deficiency 3, 4, 2.
Men who prefer oral medication over injections or topical preparations 1, 3.
Obesity-related secondary hypogonadism, where enclomiphene can be combined with weight loss efforts 5, 6.
When Enclomiphene Is Not Appropriate
Primary hypogonadism (elevated LH/FSH), because the testes cannot respond to increased gonadotropin stimulation 5, 6.
Men who do not desire fertility and prefer the slightly greater symptomatic benefit of testosterone replacement 5.
Severe hypogonadism (testosterone < 150 ng/dL) requiring rapid normalization may be better served by testosterone replacement 5.
Critical Pitfalls to Avoid
Do not use enclomiphene in primary hypogonadism; elevated LH/FSH indicates testicular failure that will not respond to further gonadotropin stimulation 5, 6.
Do not prescribe enclomiphene without confirming secondary hypogonadism (low testosterone with low/normal LH and FSH on two separate morning measurements) 5, 6, 1.
Do not expect dramatic improvements in energy, mood, or physical function; enclomiphene's benefits are confined to sexual symptoms, similar to testosterone replacement 5.
Do not continue therapy beyond 12 months if sexual function has not improved, as prolonged exposure without benefit is not justified 5.
Comparison to Clomiphene Citrate
Enclomiphene is the trans-isomer of clomiphene citrate, which is a racemic mixture of enclomiphene and zuclomiphene 4.
Clomiphene citrate 25 mg daily (the racemic mixture) has been used off-label for male hypogonadism and also raises testosterone effectively 8.
A study of 125 men treated with clomiphene 25 mg daily showed mean testosterone rising from 309 ng/dL to 642 ng/dL after 3 months 8.
If enclomiphene is unavailable, clomiphene citrate 25–50 mg three times weekly is an acceptable alternative for secondary hypogonadism with fertility concerns 5.